Review top news and interview highlights from the week ending October 8, 2021.
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The director of the Powell Gene Therapy Center at the University of Florida discussed the recent meeting of the FDA Cellular, Tissue, and Gene Therapies Advisory Committee. He touched on adverse events typically observed with gene therapies and takeaways from the meeting.
The FDA has lifted their clinical hold on Ultragenyx and GeneTx’s phase 1/2 study (NCT04259281) of GTX-102 after trial protocols were amended to lower dose levels after lower extremity weakness was observed in patients treated with high-doses.
Paul Wotton, PhD, chief executive officer, Obsidian Therapeutics, discussed the company’s pipeline and technologies. He also touched on partnerships the company has formed to collaborate on their cell and gene therapies in development.
TCR2 Therapeutics has announced positive interim data from the phase 1/2 study (NCT03907852) of gavocabtagene autoleucel (gavo-cel; TC-210) for the potential treatment of refractory mesothelin-expressing solid tumors.
Allen Feng, PhD, chief scientific officer, HebeCell, discussed advantages of induced pluripotent over hematopoietic stem cell therapies, as well as recent funding the company received from Jacobio Pharmaceuticals, intended to support the development of next-generation iPSC-CAR-NK therapies for oncologic, viral, and autoimmune indications.
Long-Term Case Series Supports CAR-T Therapy in Autoimmune Disease
March 28th 2024A 2-year evaluation of a small cohort of patients with systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis showed safety and efficacy which were supportive of additional clinical trials.
Understanding Disease Pathobiology Will be Key to Developing Cell Therapies for Autoimmune Disease
March 26th 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed the importance of further research into the root cause of MS and other autoimmune diseases.